(Q46141075)

19 December 2017

title

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome (English)

1 reference

19 December 2017

cytomegalovirus retinitis

main subject

Cytomegalovirus

0 references

1 reference

I Taskintuna

1

1 reference

19 December 2017

F M Rahhal

2

1 reference

19 December 2017

J F Arevalo

3

1 reference

19 December 2017

D Munguia

4

1 reference

19 December 2017

A S Banker

5

1 reference

19 December 2017

E De Clercq

6

1 reference

19 December 2017

W R Freeman

7

1 reference

19 December 2017

publication date

1 June 1997

1 reference

19 December 2017

published in

Ophthalmology

1 reference

19 December 2017

volume

104

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

page(s)

1049-1057

1 reference

19 December 2017

A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Cytomegalovirus retinitis: a manifestation of the acquired immune deficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Acquired immune deficiency syndrome. Ocular manifestations

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Ocular manifestations of acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Ophthalmic Involvement in Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intraocular antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930188-2

7 January 2021

10.1016/S0161-6420(97)30188-2

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

9186448

1 reference

19 December 2017